

ANNUAL REPORT **2017**



CANSEARCH

fondation de recherche
contre le cancer de l'enfant



Me Robert Hensler
President



Professor Marc Ansari
Founder and Director
of CANSEARCH

A WORD FROM THE PRESIDENT AND THE DIRECTOR **ME ROBERT HENSLER AND PROF. MARC ANSARI**

"Illness is like a robbery, a real bank robbery, it can take you violently, coldly, taking ALL that is most precious without asking. I have nothing left today but the SENTIMENT OF LOVE in my life." Esteban, 9, now deceased.

Medicine has made tremendous progress in recent years as 80% of children with cancer can be cured. However, cancer remains to date the leading cause of death from illness in children with more than 250 new cases per year, and for those who are recovering or in remission the long-term side effects of some treatments may prove to be very heavy and have a major negative impact on the quality of their life as a child, adolescent then as an adult.

The research platform in oncology and pediatric hematology created by the CANSEARCH Foundation in collaboration with the University Hospitals and the Faculty of Medicine of the University of Geneva has for this purpose led many research projects for the past six years to better understand the development of the disease and to improve existing treatments and make them less toxic through an individualized therapy approach. More than twenty people collaborate in its activity: researchers, technicians and doctoral students.

Researching the genes to understand why and how the disease evolves, then adapting the treatments to the genetics of each child: that is the challenge of this personalized medicine which aims to improve their survival.

Thanks to the combined efforts of doctors, who identify at the bedside the aspects of the treatments to be improved, and researchers who study how to provide solutions [bedtobench principle], new hopes for sick children are emerging.

This annual report on our activities in 2017 will give you an overview of the major results obtained and give you more details on how your donations are used. It will also present the new projects that we are going to or have already launched, which testify to the dynamism of our activity.

It is thanks to the great generosity that you have shown us throughout the year and during our third charity evening in September 2017 that we can continue and sustain our action.

All of you, whether you are a donor, a researcher, a physician, or a volunteer, are helping to advance research to give children with cancer a better future. Your faithful support is precious. Thank you for joining the CANSEARCH Foundation to help children.

Together we can help them fight, to face the challenge of becoming heroes in the face of the disease: "TOGETHER WE CAN ... CANSEARCH".



A stylized, handwritten signature in black ink.

Sébastien Joliat
Treasurer

FINANCIAL REPORT

Donors to the CANSEARCH Foundation have been numerous and faithful and have allowed the scientific research conducted by the Foundation to continue very favorably, especially with the launch of new projects from the year 2018. These attest to the dynamism of the laboratory activity and its internationally recognized positioning.

As a result of the increase in the Foundation's activity, the Organizational Team now includes a Secretary General [Patricia Legler] and a Donor Manager [Nathalie Martens Jacquet].

It is also fortunate to be able to count on the dedication and skills of several volunteers [Laurence Bagnoud Roth, Elena Bouvier, Alix Rivoire, Valerie Steck and Cathy Wintsch], thus limiting administrative costs.



Report of the auditors
on the limited statutory examination of

Fondation CanSearCH
Thônex

Geneva, May 14th, 2018
69/mg/8

BfB Société Fiduciaire
Bourquin frères et Bérar SA
Rue de la Corraterie 26
Case postale 5024
1211 Genève 11
Suisse

Tel +41 (0)22 311 36 44
Fax +41 (0)22 311 45 88
E-mail contact@bfbge.ch
Web www.bfb.ch

Fondée en 1892

Dear Sirs,

BfB


As statutory auditors, we have examined the financial statements (balance sheet, profit and loss statement and notes to the financial statements) of Fondation CanSearCH for the year ended December 31st, 2017.


These financial statements are the responsibility of the Board of Trustees. Our responsibility is to perform a limited statutory examination on these financial statements. We confirm that we meet the licensing and independence requirements as stipulated by Swiss law.

We conducted our examination in accordance with the Swiss Standard on the Limited Statutory Examination. This standard requires that we plan and perform a limited statutory examination to identify material misstatements in the financial statements. A limited statutory examination consists primarily of inquiries of company personnel and analytical procedures as well as detailed tests of company documents as considered necessary in the circumstances. However, the testing of operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

Based on our limited statutory examination, nothing has come to our attention that causes us to believe that the financial statements do not comply with Swiss law and the foundation's articles of incorporation.

BfB Société Fiduciaire
Bourquin frères et Bérar SA


Jean TRIBOULET
Swiss certified accountant
Auditor in charge


Jean-Paul TRIBOULET
Swiss certified accountant

Enclosures:

Financial statements consisting of:

- balance sheet
- profit and loss statement
- notes to the financial statements

BALANCE SHEET AS AT DECEMBER 31ST, 2017

[with previous year comparative]

ASSETS (CHF)	31.12.2017	31.12.2016
Current assets		
Cash and equivalent	4'993'733	3'948'314
<i>Cash</i>	4'993'733	3'948'314
Other short term receivables	1'221'165	1'004'407
<i>Down payment to Geneva University</i>	1'221'165	1'004'407
Accrued income and prepaid expenses	28'702	2'886
<i>Accrued income and prepaid expenses</i>	28'702	2'886
Total current assets	6'243'600	4'955'607
Fixed assets		
Tangible fixed assets	58'489	57'029
<i>Research equipments</i>	25'278	24'368
<i>Computer equipment</i>	33'211	32'661
Total fixed assets	58'489	57'029
TOTAL ASSETS	6'302'089	5'012'636

LIABILITIES AND EQUITY (CHF)	31.12.2017	31.12.2016
Current liabilities		
Deferred income and accrued expenses	31'621	39'926
<i>Accrued expenses</i>	31'621	39'926
Total current liabilities	31'621	39'926
Non-current liabilities		
Funds	6'170'468	4'872'710
<i>Research affected funds</i>	6'111'979	4'815'681
<i>Funds affected for fixed assets depreciations</i>	58'489	57'029
Total non-current liabilities	6'170'468	4'872'710
Total liabilities	6'202'089	4'912'636
Equity		
Equity	100'000	100'000
<i>Paid in capital</i>	100'000	100'000
Total equity	100'000	100'000
TOTAL LIABILITIES AND EQUITY	6'302'089	5'012'636

PROFIT AND LOSS STATEMENT FOR THE YEAR ENDED DECEMBER 31ST 2017

[with previous year comparative]

	31.12.2017	31.12.2016
Income	2'805'996	2'261'249
<i>Grants, private donations</i>	<i>2'805'996</i>	<i>2'261'249</i>
Direct expenses	970'684	756'948
<i>Laboratory expenses</i>	<i>151'860</i>	<i>115'320</i>
<i>Salaries, wages and other research expenses</i>	<i>747'291</i>	<i>588'323</i>
<i>Research donations</i>	<i>39'600</i>	<i>38'050</i>
<i>Fixed assets depreciations</i>	<i>31'933</i>	<i>15'256</i>
Profit from operations	1'835'312	1'504'301
General and administration expenses	540'032	171'302
<i>Fundraising events cost</i>	<i>290'411</i>	<i>22'218</i>
<i>Salaries and other benefits – administration</i>	<i>168'400</i>	<i>67'472</i>
<i>Scientific Committee fees</i>	<i>13'810</i>	<i>12'000</i>
<i>General and administration expenses</i>	<i>45'796</i>	<i>34'242</i>
<i>Accounting, audit and consultancy fees</i>	<i>21'614</i>	<i>35'370</i>
Earnings before interests & taxes (EBIT)	1'295'280	1'332'999
Financial result	2'477	-2'573
<i>Bank charges</i>	<i>-1'260</i>	<i>-3'575</i>
<i>Exchange loss</i>	<i>-801</i>	<i>-179</i>
<i>Other financial revenues</i>	<i>55</i>	<i>49</i>
<i>Exchange gains</i>	<i>4'483</i>	<i>1'132</i>
Earnings before fund affectation	1'297'758	1'330'426
Funds contributions	- 1'297'758	- 1'330'426
<i>Contribution to the research fund</i>	<i>-1'296'298</i>	<i>-1'297'662</i>
<i>Contribution to the fixed assets depreciations fund</i>	<i>-1'460</i>	<i>-32'764</i>
NET PROFIT	-	-

CanSearCH Foundation

THÔNEX

NOTES TO THE FINANCIAL STATEMENT AS AT DECEMBER 31st, 2017

FOUNDATION ORGANISATION

The Foundation is a legal entity organized under articles 80 and following of the Swiss Civil Code.

Mailing address:

Cansearch Foundation; Chemin du Pont-Perrin 6; CH-1226 Thônex

Purpose of the foundation:

Pursue exclusively general interest goals in the fields of pediatric oncology & hematology, mainly in Geneva but without exclusion from the rest of Switzerland or abroad, in particular to promote research in the fields of pediatric oncology & hematology, more specifically favoring studies of the oncology & pediatric hematology group in Geneva; promote the well-being & recovery of children with illness in the area of oncology and hematology and to support their families (cf. Foundation act for complete purpose).

BOARD ORGANISATION

In compliance with article 8 of the statutes the Board is composed of at least three members. Collective signature for two. No remuneration was paid to members of the Board during year 2017.

List of Board members, according the commercial register:

- Robert HENSLER	member - president
- Céline DENIZOT	member - vice-presidente
- Sébastien JOLIAT	member - treasurer
- Maurice MACHENBAUM	member
- Patricia LEGLER	secretary general

Founder and Director of the CANSEARCH Foundation:

- Professor Marc ANSARI

List of scientific committee members as of 31st December 2017:

- Professor Jakob PASSWEG	member - president
- Professor Sylvain BARUCHEL	member
- Professor Marina CAVAZZANA-CALVO	member
- Professor Urs MEYER	member
- Doctour Jean MICHON	member

Until 31 December 2017, the Foundation employed part-time administrative personnel:

- Patricia LEGLER	01.11.17 to 31.12.17 at 80%
- Nathalie MARTENS JACQUET	01.02.17 to 31.12.17 at 90%
- Valérie STECK	01.01.17 to 31.11.17 at 60%

APPLIED ACCOUNTING PRINCIPLES AND ACCOUNTING BODY

The Foundation's accounting is upheld according to the principles of the Swiss Code of Obligations.

The distribution of project receipts and expenditures was recorded on the basis of the calculations of the University of Geneva.

Cofida Compagnie Fiduciaire d'Informatique SA: Rue Ancienne 88 ; CH-1227 Carouge is in charge of the foundation booking.

AUDITOR

BfB Fiduciaire Bourquin frères et Béran SA ; Rue de la Corratierie 26 ; CH-1204 Genève, is the auditor.

TAX EXEMPTION

The Foundation is exempt from the cantonal and communal tax on capital and profit from fiscal period 2011 for a period of 10 years and for federal tax for an indefinite period.



THE MISSION OF THE CANSEARCH FOUNDATION

Since its creation in 2011, the CANSEARCH Foundation has been conducting research projects in Geneva into childhood cancer to better understand the disease and make the therapies more targeted and less toxic by adapting them to the genetics of the child to improve their survival. We speak of “precision medicine”, of individualized medicine.

The main childhood cancers are leukemias, brain tumors and lymphomas, and some forms are specific to children. Most often, research for adult cancers cannot be transposed to childhood cancer.

It is for this reason that the CANSEARCH Foundation was created: to allow progress for children, since less than 2% of funds dedicated to cancer research are allocated to pediatric cancers.

Thanks to the first pediatric onco-hematology research platform created by the CANSEARCH Foundation in our canton and currently having more than twenty collaborators, several research projects have been launched in Switzerland and internationally. They focus on the fields of pharmacogenomics and oncogenetics.



CURRENT PROJECTS

In 2017, the research work carried out within the research platform in pediatric oncology and hematology, focused on individualized therapy, and is divided into the following four areas:

- Pediatric Precision Medicine [Pharmacogenomics] and Hematopoietic Stem Cell Transplantation
- Liver tumors
- Brain tumors
- Oncogenetics

Pediatric precision medicine and stem cell transplantation

The CANSEARCH laboratory has more than 6 years of pharmacogenomics research experience and collaborates locally, nationally and internationally in this field. Our expertise allows us to adapt the doses of certain drugs for the treatment of pediatric cancers and to use genetic models to predict the response to these treatments.

One of the concrete results of this research has been directly applied in the clinical activity for sick children where more than 70 children in Geneva have been transplanted in the last ten years. In stem cell transplantation as a treatment for leukemia, the chemotherapeutic agent Busulfan is often administered as a conditioning regimen prior to such transplantation. This agent can induce toxicities for the child. Thanks to our research, we can now adapt the dose of Busulfan to be administered according to the patient's genetic profile and thus individualize their treatment in order to reduce the toxicity and improve the child's survival.

Several studies are currently open in this area at the instigation of the CANSEARCH Foundation: two of them in more than 20 countries including the FORUM study on lymphoblastic leukemia and a third that will begin in 2018 on myeloid leukemia [study MYECHILD], bringing to over 600 the number of children worldwide studied by CANSEARCH.


These results attest to the importance of being able to determine the germinal DNA of pediatric patients with cancer in order to identify those who would be at greater risk of poorly supporting treatment, developing toxicities, rejecting transplants or relapsing.

It is for this purpose that our laboratory is also conducting a DNA sequencing project, in collaboration with the CHU Sainte-Justine Hospital in Canada and with the Swiss Institute of Bioinformatics in Geneva. Among others, a grant from the Swiss National Fund also supports this project.

Liver tumors (Kids liver CANSEARCH group)

The CANSEARCH laboratory participates in an international collaboration [Europe, Japan and USA] in the field of liver cancer, in particular with the International Society of Pediatric Oncology [SIOPeL]. It has established a system of classification of the risk of relapse in liver tumors leading to the individualization of chemotherapeutic treatment that will be useful to all researchers in this field. The new study that will follow [Pediatric Hepatic International Tumor Trial - PHITT] will aim, among other things, to validate this classification prospectively. This first step was the subject of an article published in 2017 in Lancet Oncology and this project is supported at European level by a prestigious Horizon 2020 grant.

In addition, and to enable its development, a statistician has been hired in Switzerland following a grant from the Swiss Cancer League, of which Prof. Marc Ansari was the main instructor. As a result of this research, an important article appeared in the New England Journal of Medicine that will allow the use of a new drug that reduces auditory toxicity for children with liver cancer, hepatoblastoma.



Oncogenetics

Neuroblastoma

In recent years, our work on neuroblastoma, the most common extracranial tumor in very young children, has shown that the loss of the ATM gene may play a role in the aggressiveness of this tumor. It is by studying certain biological pathways in which ATM is essential that the question of the therapeutic role of the reactivation of some of the proteins arose. One of the central proteins that can be reactivated is p53, in particular by a small molecule, PRIMA 1-MET. It is currently undergoing evaluation in adults but has never been studied in pediatric cancers.

During the year 2017, Dr. Fabienne Gummy-Pause, accompanied by researchers, carried out various in vitro experiments to study the efficacy of PRIMA1-MET on neuroblastoma cells and to better understand its action mechanisms. The results are promising, researchers will now be able to analyze the effects of this molecule in combination with anti-cancer drugs. Following these results, and if these are conclusive, this molecule could enter Phase I / II clinical studies. Indeed, the neuroblastoma having a mortality rate of the order of 15%, it is essential to find new therapeutic approaches. The results already obtained by our researchers are currently submitted for publication in an international journal and will be presented at a forthcoming congress on neuroblastoma (ANRA) to be held in the USA in May 2018.

Brain tumors

Pediatric neuro-oncology

Brain tumors are the second most common type of cancer in children, and some are unfortunately still too often characterized by low survival rates. Nearly half of these tumors are gliomas. In this area of pediatric neuro-oncology, tumors of the child's central nervous system involve a distinct entity that could be treated differently based on its genetic and epigenetic traits.

Thus, during the year 2017, our research platform tested the toxicity and efficacy of several treatments, especially for children with high grade gliomas and medulloblastomas.

In cohorts of patients treated homogeneously, we identified that biological parameters and histology defined the prognosis that young children had for having metastatic medulloblastoma.

Thanks to a global collaboration (meta-analysis), molecular data of some 1000 patients with high-grade gliomas were analyzed and Dr. André Von Büren was able to validate a potentially large number of clinical and molecular markers.

These efforts are aimed at improving the treatment of brain tumors which, unfortunately, suffer from very low survival rates in children.



HOW DO WE MEASURE THE ADVANCES OF OUR RESEARCH AND WHAT RESULTS HAVE WE ACHIEVED?

Over time

Medical research, even when applied, requires significant financial investment and our research projects are spread over periods of three to six years, which is the average for medical research. That's why the CANSEARCH Foundation's donors are so valuable and indispensable to enable research to progress.

Results obtained:

After 6 years of existence, more than 600 children in Geneva and around the world have benefited from our pharmacogenomic studies to adapt the dose of the chemotherapeutic agent Busulfan to the genetics of children during hematopoietic cell transplantation in order to reduce the toxicity of the treatment and thus increase their chances of survival.

Through publications and presentations at national and international conventions

Researchers publish in specialized scientific journals the progress of their research as they progress through articles or abstracts. Their articles can then be cited by other researchers who have recognized their value, or not yet, because their research is too far ahead of its time. In any case, the results of our research are accessible to the entire scientific community, which can benefit from our advances in oncology and pediatric hematology.

The presentation of scientific advances at national and international conferences and congresses is a way for researchers to share the results of their studies with experts in their field.

Transmitting results as an abstract to a convention is already a success. Having the privilege of being invited to present them orally before all congress participants is the highest confirmation of success for a researcher.

Results obtained:

From 2011 to the end of 2017, 108 articles have been published by researchers from the CANSEARCH Foundation, 82 abstracts were presented at international conferences, 27 at national conventions and 36 abstracts were written (but not published).

For the twelve active researchers from the CANSEARCH platform this constitutes a constant and high number of publications.

A major oral presentation of our results in pharmacogenetics was made by Prof. Marc Ansari, invited to the congress of the American Society of Hematology in Atlanta (ASH) in December 2017. The ASH is the world reference for blood diseases and its congress welcomes more than twenty thousand world experts.

Through competitive institutional scholarships


Obtaining a scholarship involving a competitive selection process is a recognition of the importance of research and its relevance from a scientific point of view.

Results obtained:

Since 2011, 4 competitive institutional grants have financed our projects, awarded by the Swiss National Fund, the Swiss Cancer League, the Geneva Cancer League and the Horizon 2020 program of the European Commission.

Thanks to the possibility to open new studies validating the previous ones

The possibility of opening new studies on a particular aspect of a research previously conducted to validate initial results, is also a factor in the advancement of medical research.



Results obtained:

Our results obtained in pharmacogenomics now allow us to test our hypotheses with respect to two particular types of leukemia: acute lymphoblastic leukemia [FORUM project started in 2012] and acute myeloid leukemia [MYECHILD project for 2018]. They will also allow us to prospectively test, for the future, our conclusions [BUGENES project in 2019] and to set up an innovative germplasm biobank project [from 2018].

Thanks to the ability to create collaborations

Having clinical and biologic data from a large number of child patients and many samples of their DNA is crucial to adding value to the research we do. This requires us to affiliate to various organizations active in our research fields around the world and to collaborate with medical centers in several countries to obtain them. Only quality research allows the creation of such collaborations and gives visibility to the studies carried out.

Results obtained:

The CANSEARCH Research Laboratory is affiliated with more than 20 national and international organizations in the field of pediatric onco-hematology and is in contact with over seventy medical centers around the world to obtain clinical and biological data.

AFTER 6 YEARS, CONCRETE RESULTS:



> 600 children in Geneva and around the world benefit from our research



> 20 affiliations to national or international organizations



> 20 researchers, technicians and doctoral students



> 70 medical centers around the world with which we collaborate



108 published articles and 107 abstracts presented



3 new studies launched in 2017-2018-2019



> 100 presentations of our research at conferences in Switzerland and around the world



1 appointment as assistant professor for Prof. Marc Ansariari



4 institutional scholarships obtained

HOW ARE YOUR DONATIONS USED?

In 2017 donations collected from our generous donors, net of operating expenses, were entirely allocated to our various research projects in pediatric onco-hematology in the fields of pharmacogenetics, stem cell transplantation, liver tumors, brain tumors and oncogenetics, the main ones of which are:

- Impact of pharmacogenetics on children with lymphoblastic leukemia (FORUM) and benefiting from hematopoietic stem cell transplantation: multicenter study including more than 600 children and open in more than 20 countries. Support from the Swiss National Fund. Project accepted as a European study by the European Group for Blood and Marrow Transplantation (EBMT) and as a Swiss study by the Swiss Pediatric Oncology Group (SPOG).
- Effects of pharmacogenetics on the pharmacokinetics of Busulfan in children undergoing hematopoietic stem cell transplantation: a multi-center study involving 250 children. Support from the Swiss National Science Foundation and the Geneva Cancer League and the EBMT.
- Influence of pharmacogenetics on acute myeloid leukemia in children (MYECHILD): multicenter international study. Support of the Swiss Pharmacogenomics and Individualized Therapy Group and the European Society of Pharmacogenomics and Individualized Therapy.
- Studied collaboration with Canada (CHU St Justine) on genetic determinants in pediatric stem cell transplants.
- Creation of an international DNA database of children who have undergone stem cell transplantation.
- Project to create a germline DNA biobank for children who have survived cancer.
- Clinical study on childhood cancer in Switzerland. Study of the International Society of Pediatric Oncology (SIOPEL). Horizon 2020 Scholarship
- International Program for Liver Cancer Research in Children (R. Maibach), SIOPEL.

- International collaboration on childhood liver tumors (CHIC) with stratification of risk of hepatoblastoma.
- Study of the pharmacogenomics of neuroblastoma.
- Study on the role of the ATM gene in neuroblastoma and identification of the impact of certain treatments.
- High-grade glioma study in pediatric neuro-oncology.

The CANSEARCH Foundation's research projects span an average period of three to six years and their budgets reach several million Swiss francs per project.

To ensure the sustainability of its projects, the CANSEARCH Foundation ensures that it has sufficient liquidity to carry out its research projects to completion.



NEW PROJECTS

The BUGENES project

The “BuGenes” project consists of establishing, by means of an algorithm based on the variation of genes that can dictate the response to the patient’s medications (pharmacogenomic), the dose of the chemotherapeutic agent Busulfan to be administered before stem cell transplantation (HSCT) to cure the patient of cancer.

This project, centralized in Geneva, will compare a study based on the identified genetic variations of the child with a study based on the factors traditionally used such as age, weight or size to determine if genetic factors allow to better individualize the therapy. Patients aged 0 to 20 years from different medical centers and requiring HSCT will be recruited for this purpose and will form cohorts of patients more numerous than those existing to date, which will be the added value of this study.

The MYECHILD project

The “MyeChild” project, centralized and coordinated in Geneva for its pharmacogenomic part, consists of an international collaboration, ie a recruitment, as early as 2018, particularly in France, Great Britain and probably also in Australia, of DNA samples of approximately 500 patients under 18, who have recently been diagnosed with acute myeloid leukemia. The goal is to test a number of therapeutic strategies against various chemotherapeutic agents in order to improve the results according to the pharmacogenomics.

Indeed, acute myeloid leukemia is a rare disease in children and adolescents, but with a high mortality rate. In general, children with acute myeloid leukemia have a cure rate within 5 years of 65-75%, unlike acute lymphoblastic leukemia for which we can talk about 80-90% cure rate.

The biobank project

This project consists of the establishment of a biobank by our research laboratory, based in Geneva but of national scope, which will have the capacity to store germinal DNA samples of all children in Geneva and Switzerland who have been affected by cancer or children newly diagnosed with cancer.

This biobank will be open to researchers from all over Switzerland to increase research in this area. This represents a real lever of discovery in the field of child cancer. The biobank will be located in Geneva and is a partnership between the University Hospitals of Geneva, the University of Geneva and the CANSEARCH Foundation. It will also work with Genome Center at Campus Biotech for DNA sequencing. The already existing elements of this biobank have been very positively evaluated by the HUG, making it possible to pursue with optimism the development of this project.



A LOOK BACK AT PICTURES FROM THE EVENING



1



2



3




4



5



6



7



8

The CANSEARCH Foundation evening is organised every two years and was held on September 14, 2017. Most of its costs are sponsored before the event is held.

1. Board Members
2. 850 people were present at the Arena
3. Speech by the President, Me Robert Hensler
4. The children's choir of the onco-hematology unit sings for CANSEARCH
5. Speech by the Director, Prof. Marc Ansari
6. The singer Cali
7. The auction led by the famous Laurien Hessels
8. The tennis champion Stan Wawrinka

CHARITABLE FUNDRAISING ACTIONS [CANDO]

Each of your donations, regardless of their size, are invaluable to us and help advance our research.

Many groups of actions, faithful or punctual, called "CANDO", set up by volunteers, by their families and friends, have once again supported the CANSEARCH pediatric onco-hematology platform. We graciously thank them for their actions!

In 2017, the funds raised by these various actions amount to a little more than CHF 128,000 and thus make it possible to finance, partially or totally, several researchers' salaries.

Here are the main CANDOs set up during the year 2017:

- **CANFIGHT FOR VICTORIA**

In memory of Victoria, who died at the age of 10, her family and friends wanted to join forces to actively support the CANSEARCH Foundation's research.

Thanks to generous donors and several events, this action group funded part of the new myeloid leukemia research project.

- **CANGIVE**

To celebrate a birthday, a piano recital by Nelson Goerner was given at the Saanen Church [Gstaad] in support of the CANSEARCH Foundation.

There are many birthday's and weddings where faithful donors have invited their friends to come forward to the Foundation with a donation rather than a gift. At the time of the death of a relative, several friends of the Foundation wished to support CANSEARCH in place of flowers.

- **CANSAIL**

The Denebolettes, passionate women sharing the same values, gathered on a 19.50 meter Bounty sailboat, wished to join forces with CANSEARCH by raising funds for the Saint-Tropez Ladies Cup. A beautiful adventure!

- **CANDUBAI**

While celebrating their birthdays, two couples of friends of the Foundation took advantage of this event to introduce the Foundation to their friends in Dubai. This initiative led them to support the Foundation in the form of individual donations. A great way to spread CANSEARCH beyond Switzerland!



- **CANMARKET**

Throughout the year, various sales of pastries, caps or pens were held at various events for the benefit of the Foundation.

- **CANRUN**

A friend of the Foundation ran the Berlin Marathon in support of CANSEARCH. His friends and acquaintances have mobilized with him in this great challenge.

The Foundation was also present for the fourth year in a row at the Geneva Race for Gift solidarity race. More than 30 participants ran for the Foundation.

- **CANWALK**

The 4th edition of the CANWALK in Gstaad brought together over 100 walkers, children and adults for a walk followed by a picnic in the Bernese Oberland.

The "March du Coeur" in Carouge celebrated its 20th edition. Nearly 200 people rallied on a beautiful fall day to walk in CANSEARCH's favor.

- **CANSING**

The "Califrenzies" choir entertained their fans during a "Best of" which revisited the best moments of their previous shows. The full benefits of this evening have been donated to the CANSEARCH Foundation.

- **CANLOVE**

Faithful and precious partner of the CANSEARCH Foundation, Le Fleuriste des Augustins has reiterated its support for Valentine's Day. For each bouquet bought today, 10% was donated to CANSEARCH!



SPECIAL THANKS TO

Friends,
Volunteers,
Researchers,
Donors,
Families,
Volunteer members of the Board of Trustees,
Members of the Honorary Committee,
Partners,
Professors and doctors of the Scientific Committee,
Sponsors

Once again this year, you have supported us. A huge thank you to all who have helped advance research against childhood cancer, the only way to bring more healing and more effective treatments!

TOGETHER WE CAN...CANSEARCH

THANK YOU

IMPRESSUM

Publisher

CANSEARCH Foundation
Chemin Pont-Perrin 6
CH - 1226 Thônex
T. +41 76 679 45 63
info@cansearch.ch
www.cansearch.ch

Mirabaud & Cie

Boulevard Georges-Favon 29
CH - 1204 Geneva
Account number: 508397
Swift: MIRACHGGXXX
IBAN: CH10 0877 0000 0005 0839 7


Postal account

Account number: 12-189333-1
Swift: POFICHBEXXX
IBAN: CH12 0900 0000 1218 9333 1

For further information

Patricia Legler
Secretary General
patricia@cansearch.ch

Nathalie Martens Jacquet
Donor Manager
nathalie@cansearch.ch



CANSEARCH

fondation de recherche
contre le cancer de l'enfant